BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 182 filers reported holding BRIDGEBIO PHARMA INC in Q1 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $461,238 | +53.3% | 17,491 | 0.0% | 0.00% | +100.0% |
Q2 2023 | $300,845 | +28.4% | 17,491 | +23.7% | 0.00% | 0.0% |
Q1 2023 | $234,358 | +117.6% | 14,135 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $107,709 | +7.7% | 14,135 | +40.0% | 0.00% | 0.0% |
Q3 2022 | $100,000 | +8.7% | 10,097 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $92,000 | -9.8% | 10,097 | 0.0% | 0.00% | 0.0% |
Q1 2022 | $102,000 | -44.0% | 10,097 | -7.7% | 0.00% | 0.0% |
Q4 2021 | $182,000 | -51.7% | 10,935 | +36.1% | 0.00% | -50.0% |
Q3 2021 | $377,000 | -23.1% | 8,035 | -0.1% | 0.00% | -33.3% |
Q2 2021 | $490,000 | +59.1% | 8,045 | +61.1% | 0.00% | +50.0% |
Q1 2021 | $308,000 | – | 4,995 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |